Flutivent

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Flutivent

Quick Facts

Component Drug Class Action
Fluticasone Inhaled Corticosteroid (ICS) Reduces inflammation in the lungs
Salmeterol Long-Acting Beta-Agonist (LABA) Relaxes airway muscles, keeping them open

Flutivent is a prescription combination medication administered via inhalation to provide long-term maintenance treatment for respiratory conditions such as asthma and Chronic Obstructive Pulmonary Disease (COPD) in adults and adolescents. The inhaler contains two active pharmaceutical ingredients: fluticasone (a corticosteroid) and salmeterol (a long-acting beta-agonist or LABA).

The fluticasone component works as an anti-inflammatory agent, reducing swelling and irritation in the airways to help prevent asthma symptoms. Salmeterol acts as a bronchodilator; it relaxes the muscles around the airways in the lungs, which helps them stay open and facilitates easier breathing.

This medication is specifically intended for individuals whose conditions are not adequately controlled by an inhaled corticosteroid alone or whose severity warrants treatment with both an ICS and a LABA. Important Safety Note: Flutivent is a preventative medicine and should never be used to treat a sudden, acute attack of asthma or bronchospasm. A separate, short-acting 'rescue' inhaler is required for immediate symptom relief.

What side effects are possible with Flutivent ?

Possible Side Effects and Safety Information

The safety profile for Flutivent (Fluticasone/Salmeterol) is based on classifications detailed in official government regulatory documents, which group possible adverse reactions by frequency and physiological system.


Frequency-Classified Adverse Reactions

Adverse effects are categorized based on their incidence in clinical trials:

  • Very Common / Common: Reactions reported with higher frequency include headache, upper respiratory tract infection, oral candidiasis (thrush), pharyngitis (sore throat), and dysphonia (hoarseness).
  • Uncommon / Rare: These include immediate hypersensitivity reactions (e.g., rash, swelling), and paradoxical bronchospasm, which is an acute, sudden worsening of breathing immediately after administration.

Serious Adverse Reactions and Safety Constraints

The official labeling notes several clinically significant warnings. The medicine carries a documented risk of pneumonia specifically in patients with COPD. Systemic exposure to the corticosteroid component may lead to adrenal suppression or hypercorticism.

Potential cardiovascular effects, such as irregular heart rhythm or increased heart rate, are associated with the long-acting beta-agonist component. This medication is strictly restricted to long-term maintenance treatment and must not be used for treating acute asthma attacks or rapidly worsening symptoms.

Duration-Related Effects: Prolonged exposure may be associated with a reduced bone mineral density and the potential development of cataracts or glaucoma.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents describe that overdose symptoms for this combination are primarily driven by excessive beta-adrenergic stimulation from the salmeterol component. Manifestations include tachycardia (fast heart rate), tremor, palpitations, headache, nervousness, and metabolic abnormalities such as hypokalemia and hyperglycemia.

Overdose of the fluticasone component, particularly after chronic exposure to high doses, carries the risk of adrenal suppression and hypercorticism. Acute overdose may cause temporary adrenal function suppression.

Severe Outcomes and Required Action

Severe outcomes documented in official labeling include arrhythmia (irregular heartbeat), seizures, and the risk of a life-threatening acute adrenal crisis resulting from severe HPA-axis suppression. Regulators mandate that individuals must seek immediate medical attention or contact emergency services if a suspected overdose results in collapse, seizures, trouble breathing, or unresponsiveness. Urgent medical assessment is also required for a sudden and progressive deterioration in disease control.

Management and Constraints

Management is described as symptomatic and supportive treatment, requiring cardiac monitoring and procedures such as potassium supplementation. Official labeling cautions against using Flutivent in combination with another Long-Acting Beta-Agonist (LABA) due to the increased risk of overdose.

Therapeutic Uses of Flutivent

Main Uses of Flutivent

Flutivent is a maintenance medication used for the long-term management and prevention of symptoms associated with chronic respiratory conditions. It is primarily utilized in the following contexts:

  • Asthma Management: It is indicated for the prophylactic treatment of asthma. Regular use helps to reduce the frequency and severity of asthma attacks by addressing the underlying inflammation in the airways.
  • Chronic Obstructive Pulmonary Disease (COPD): It is used as a maintenance treatment for patients with COPD, including chronic bronchitis and emphysema, to help manage ongoing respiratory symptoms.

Mechanism of Action

Flutivent contains fluticasone propionate, a corticosteroid that exerts a local anti-inflammatory effect within the lungs. When inhaled, the medication works by:

  • Reducing swelling and irritation in the lining of the bronchial tubes.
  • Decreasing the production of excess mucus in the airways.
  • Lowering the sensitivity of the airways to external triggers, such as allergens or cold air.

Expected Benefits

By consistently managing airway inflammation, Flutivent provides several therapeutic benefits aimed at improving respiratory function over time:

  • Symptom Reduction: Regular use can lead to a decrease in daily symptoms such as wheezing, coughing, chest tightness, and shortness of breath.
  • Improved Lung Function: By keeping the airways open and less inflamed, the medication helps maintain better overall airflow.
  • Prevention of Exacerbations: One of the primary goals of treatment is to reduce the likelihood of acute flare-ups or worsening of symptoms that might otherwise require emergency medical intervention.
  • Enhanced Daily Activity: Effective control of chronic respiratory symptoms can support a patient's ability to engage in routine physical activities with less respiratory distress.

Regulatory References

  1. NIH MedlinePlus overview of Fluticasone and Salmeterol

Eligibility and Restrictions for Use

Official Eligibility Status

Flutivent is officially approved for the long-term maintenance treatment of persistent asthma and COPD. Eligibility is strictly defined by regulatory authorities based on age and clinical status.

  • Approved Populations: Adults and adolescents (aged 12 years and older), and pediatric patients (aged 4 to 11 years) for asthma, provided their condition is not adequately controlled by an inhaled corticosteroid alone.
  • Use Not Established: Safety and efficacy have not been established in children younger than 4 years of age.
  • Contraindications (Must Not Use): Flutivent is contraindicated for the primary treatment of acute asthma attacks or sudden bronchospasm. It must also not be used by patients with a known severe hypersensitivity to any ingredient (including milk proteins in some formulations) or by those concurrently taking another medicine containing a Long-Acting Beta-Agonist (LABA).
  • Use with Caution: Special caution is advised for patients with moderate to severe hepatic impairment (liver disease), certain cardiovascular disorders, or active systemic infections. No dose adjustment is required for renal impairment.
  • Reproductive Status: Use during pregnancy is permitted only if the potential benefit justifies the potential risk. For lactation, the decision is to discontinue the drug or discontinue breastfeeding.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Flutivent (fluticasone and salmeterol) by two primary categories: those affecting metabolism and those causing additive or opposing effects.

Contraindicated Combinations

Co-administration with certain medicinal products is formally prohibited due to the risk of serious adverse outcomes, as documented by regulatory authorities:

  • Non-Selective Beta-Blockers: These agents are contraindicated because they pharmacodynamically oppose the action of salmeterol, potentially leading to severe bronchospasm.
  • Monoamine Oxidase Inhibitors (MAOIs) and Tricyclic Antidepressants (TCAs): These are contraindicated due to the potential for potentiating the cardiovascular effects of the salmeterol component.
  • Ritonavir: This potent inhibitor of the CYP3A4 enzyme is prohibited because it significantly increases the systemic exposure of both fluticasone and salmeterol.

Pharmacokinetic and Pharmacodynamic Interactions

Interactions involving metabolism or additive biological effects require caution:

  • Potent CYP3A4 Inhibitors (e.g., Ketoconazole): These products reduce the metabolic clearance of fluticasone, a CYP3A4 substrate, leading to an officially documented increase in its systemic plasma exposure.
  • Potassium-Depleting Diuretics: Co-administration results in an additive pharmacodynamic risk of hypokalemia.
  • Other Sympathomimetic Agents: These agents carry an additive pharmacodynamic risk of cardiovascular effects when co-administered.

Regulatory documentation also notes that severe hepatic impairment may increase systemic exposure to both drug components, potentially heightening the risk of adverse interactions.

Mechanism of Action

How Flutivent Works (Mechanism of Action)

Flutivent (likely Fluticasone) functions as a synthetic corticosteroid, exerting its effects primarily by modulating fundamental anti-inflammatory pathways within target cells.


Targeting Cellular Glucocorticoid Receptors

The drug's active compound initiates its mechanism by binding with high affinity to intracellular glucocorticoid receptors (GRs) found in the cell's cytoplasm. This interaction forms a drug-receptor complex that translocates into the cell nucleus, placing the drug within the mechanistic domain of nuclear receptor agonism. This step is essential to influence core mechanisms underlying the drug’s pharmacological effect profile.


Gene Regulation and Suppression of Inflammatory Pathways

Once in the nucleus, the complex modulates gene expression through trans-repression, actively blocking pro-inflammatory transcription factors like NF-kappaB from activating inflammatory genes. This action modifies early molecular steps, suppressing the synthesis and release of a wide range of inflammatory mediators (e.g., cytokines and chemokines). This action influences the signaling patterns within the targeted pathways.


Modulation of Inflammatory Responses

By suppressing mediator synthesis, the drug limits the infiltration and activity of inflammatory cells (such as eosinophils) and alters local blood vessel permeability. This mechanistic domain influences core inflammatory systems, leading to an alteration in downstream physiological signaling and alters the downstream effect of excessive mediator activity, which involves changes in local vascular permeability and tissue fluid dynamics.

Dosage and Administration Information

Flutivent is officially used for long-term maintenance treatment of chronic respiratory conditions and is strictly administered via oral inhalation. It is supplied in various dosage strengths delivered through a Dry Powder Inhaler (DPI) or a Pressurized Metered-Dose Inhaler (pMDI).

The standard frequency pattern is twice daily, with doses required to be taken approximately 12 hours apart (morning and evening). The specific dosage strength is selected based on the approved condition. For adult COPD maintenance treatment, the use is standardized to the 250/50 mu g strength twice daily. For asthma management, a wider range of strengths is available, up to 500/50 mu g twice daily. For pediatric patients aged 4 to 11, a specific lower strength combination is used.

Administration requires adherence to specific procedures. It is essential to rinse the mouth with water and spit it out immediately after each use of the medication. If a dose is missed, it should be skipped, and the next dose must be taken at the scheduled time; double dosing is not permitted. Flutivent is not indicated for the relief of acute symptoms and is exclusively for chronic management. Additionally, patients are restricted from using any other medicine that contains a Long-Acting Beta-Agonist (LABA).

Recent Clinical Evidence

Flutivent: Recent Clinical Evidence

The research supporting the use of Flutivent for chronic respiratory conditions comes primarily from clinical studies designed to understand how the combination of its two components explores symptom patterns over defined time intervals. This evidence base is rooted in Randomized Controlled Trials (RCTs) and comprehensive meta-analyses that compare the medication to single-component therapies or to a placebo. Research does not determine whether an individual will respond similarly.


Evidence for Maintenance Treatment of Persistent Asthma

This section summarizes the body of research, primarily Randomized Controlled Trials (RCTs) and meta-analyses, that examined Flutivent's effect on functional measures and exacerbation frequency in adults, adolescents, and children with persistent asthma. For persistent asthma, Flutivent was studied for long-term maintenance in individuals whose condition was evaluated in research contexts involving fluctuating or unstable symptoms. Studies were conducted to measure outcomes related to functional imbalance in the lungs, such as changes in FEV1, and outcomes describing episodic or acute changes, such as the rate of severe flare-ups.

Research so far indicates patterns where the combination was observed in studies designed to evaluate changes in measured lung function compared to the inhaled steroid component alone. Studies also reported data show patterns related to the frequency of severe flare-ups. Furthermore, trials applied in studies examining patient-reported experiences monitored the frequency of reliance on using a rescue inhaler. What remains uncertain is how Flutivent compares directly to other specific combination therapies; the existing comparative evidence is limited and findings were often mixed.


Evidence for Maintenance Treatment of Chronic Obstructive Pulmonary Disease (COPD)

This part reviews the large-scale, long-term clinical trials that evaluated the use of Flutivent for managing COPD, focusing on the research that measured airflow obstruction metrics and the rate of severe COPD flare-ups. Flutivent was evaluated in numerous large-scale, long-term RCTs (some spanning up to three years) that focused on adults with stable COPD who often had moderate-to-severe airflow limitation. The research examined outcomes related to functional imbalance (FEV1) and outcomes capturing phases of heightened symptom activity (annual rate of COPD flare-ups).

Studies reported patterns related to measured changes in lung function and patterns related to observed changes in exacerbation rates when compared to a placebo. Trials studies monitoring survival reported no statistically significant difference in overall mortality. A higher incidence of specific events, like pneumonia, was observed in some studies using the inhaled corticosteroid component.


Long-Term Studies and Durability of Follow-Up

The follow-up durations were observed in a range, from short-term (12 weeks) to long-term survival studies in COPD (up to three years). Limited information for long-term outcomes beyond the initial major trials means that the full effects of continuous use over many years are still being characterized, and data for these outcomes are still emerging.


Evidence in Specific Patient Populations

Pediatric groups (children aged 4 to 11 years) were evaluated in certain asthma trials, but the results apply only to the populations studied. Data for certain groups remain insufficient, such as for very mild COPD or asthma patients outside the studied age ranges.


Areas of Research Uncertainty and Gaps

A major area of uncertainty is the absence of findings related to benefit on overall mortality in long-term COPD trials. This indicates that while the combination was evaluated for its association with changes in symptom patterns and exacerbation frequency, research does not determine that it influences long-term survival. Comparative evidence is lacking for many head-to-head trials against all other similar ICS/LABA combinations, meaning that certainty remains low regarding whether Flutivent explores if there are specific differences over other products in its class.

Key Studies & References

  1. Fluticasone and Salmeterol Oral Inhalation: MedlinePlus Drug Information
  2. Meta-analysis: effects of adding salmeterol to inhaled corticosteroids on serious asthma-related events

Frequently Asked Questions (FAQ)

Common questions about Flutivent (FAQ)


Q: Does Flutivent contain any common allergens, such as lactose or gluten?

According to the official product information, Flutivent inhalation powder contains lactose monohydrate as an inactive ingredient. The label notes that use is contraindicated for patients with a known severe milk protein allergy. The labeling does not provide specific information about gluten content.


Q: What general expectations are there regarding long-term use of Flutivent?

Flutivent is described as a long-term maintenance treatment for chronic conditions. Official information indicates that prolonged use may be associated with certain risks, such as a reduction in bone mineral density and the potential development of cataracts or glaucoma. The need for ongoing clinical monitoring may be discussed with a healthcare provider if the medication is used long-term.


Q: Is it true that Flutivent is not recommended for people with a specific type of heart condition?

Official labeling indicates that caution is advised for people with certain cardiovascular disorders when considering this product. This includes individuals with conditions like coronary insufficiency (limited blood flow to the heart), specific cardiac arrhythmias (irregular heart rhythms), and hypertension (high blood pressure).


Q: How soon after starting Flutivent should a person see an improvement in their condition, based on study results?

Flutivent is specifically intended for long-term maintenance and is not intended for quick relief of sudden or acute symptoms. Studies assessing the full therapeutic benefits of the medication typically monitor effects over weeks of continuous, regular use.


Q: What is the general shelf life of Flutivent before it expires?

Regulatory guidelines for Flutivent devices state that the inhaler should be discarded when the dose counter reaches '0' or one month after it is first removed from its protective foil pouch, whichever happens first. The overall expiration date for the unopened product is found on the packaging.


Q: Can Flutivent affect dental health or cause oral issues?

Official safety information indicates that a common oral issue associated with use is oral candidiasis, often called thrush, which is a fungal infection of the mouth and throat. To help minimize this risk, the label includes a recommendation to rinse the mouth with water and spit it out immediately after each time the medication is used.


Q: Are there limitations on using Flutivent for people who have high blood pressure?

Official regulatory documents indicate that caution is advised for patients with hypertension (high blood pressure). This is due to the potential for certain cardiovascular effects that are associated with the long-acting beta-agonist component of the medicine.


Q: Is a dry mouth a known or common side effect of Flutivent?

Dry mouth is not listed among the common or very common side effects reported in clinical trials for Flutivent at recommended doses. However, official information notes that dry mouth has been reported as a symptom in some cases of drug overdosage.


Q: Why is Flutivent only available with a prescription?

Flutivent is available only with a prescription because it is indicated for the long-term management of chronic respiratory diseases. Regulatory classification notes that medicines containing a Long-Acting Beta-Agonist (LABA) must be used under careful clinical management and supervision.


Q: Are there any specific drug interactions for Flutivent other than the ones listed in the official prescribing information?

Official regulatory documents list specific, serious interactions that must be avoided or used with caution, such as with beta-blockers, MAOIs, and potent CYP3A4 inhibitors. While the official label provides the most critical and documented interaction information, it does not provide an exhaustive list of every possible interaction with every substance.


Q: Can I use Tylenol (acetaminophen) while also using Flutivent?

Regulatory interaction databases suggest that there is no known clinically significant interaction between the active components of Flutivent and acetaminophen (the ingredient in Tylenol).


Q: Does Flutivent have a documented impact on blood sugar levels?

Official safety information indicates that the product may potentially cause hyperglycemia, which is an elevated level of blood sugar. The regulatory documents note that caution is advised when the medication is administered to patients with diabetes.


Q: What are the inactive ingredients (known components) that make up Flutivent?

Flutivent contains the two active ingredients, fluticasone propionate and salmeterol xinafoate. For the inhalation powder formulations, the main inactive ingredient listed in regulatory documents is lactose monohydrate.


Q: Can Flutivent cause or contribute to mood swings or feelings of anxiety?

Anxiety is listed in regulatory documents as an uncommon side effect of Flutivent. Other central nervous system effects such as nervousness and certain mood changes have also been reported through postmarketing surveillance.


Q: Does Flutivent interact with common substances like grapefruit juice?

Regulatory documents indicate that grapefruit juice may interact with Flutivent. Grapefruit juice is a strong CYP3A4 inhibitor, which can significantly increase the systemic exposure of the fluticasone component in the body.


Q: Is it normal to feel a slight tremor or restlessness after using Flutivent?

Official safety information notes that tremor (shakiness) is listed as an uncommon side effect associated with the product. Additionally, restlessness is noted in postmarketing reports compiled by regulatory authorities.


Q: What common over-the-counter cold medicines have documented interactions with Flutivent?

Official documents note that caution is advised when using other sympathomimetic agents, which are often found in over-the-counter cold, allergy, or diet medicines. This caution is based on a potential additive risk of cardiovascular effects when these medicines are used with the salmeterol component of Flutivent.


Q: Is Flutivent considered to be addictive or habit-forming?

The regulatory agency has not classified this medication as a controlled substance. This official classification indicates that the product carries no documented risk of being addictive or habit-forming.


Q: What is the general follow-up schedule suggested for patients who are using Flutivent?

The official product label notes that assessment at regular intervals by a healthcare provider is suggested while using Flutivent. This ongoing supervision is noted because patients may require monitoring for certain potential side effects, such as signs of adrenal suppression or oral infection.


Q: Is Flutivent currently available as a generic medicine?

Generic versions of Fluticasone/Salmeterol inhalation products have been officially FDA-approved and are available in the market.


Q: How long after a person stops using Flutivent does the substance remain in the body?

Pharmacokinetic data from the official prescribing information shows that the Salmeterol component has an elimination half-life of approximately 5.5 hours. This refers to the time it takes for half of the substance to be eliminated from the body.


Q: What is the factual difference between Flutivent and its original branded version?

Generic versions of Fluticasone/Salmeterol are officially FDA-approved as therapeutically equivalent to the original brand-name product. This classification requires that the generic product be chemically the same, contain the identical active ingredients, and meet the same official standards for efficacy and safety.

How should Flutivent be stored and disposed of?

The storage and disposal of Flutivent, a dry powder inhaler, must strictly follow official regulatory guidelines to maintain its stability.

Storage Requirements

The device must be stored at Controlled Room Temperature, defined as 20^circ to 25 C (68^circ to 77 F), with permitted excursions up to 30 C (86 F). It is required to keep the inhaler in a dry place, protected away from direct heat and sunlight.

  • Moisture Restriction: The device must never be washed or placed in water.
  • Child Safety: The medication must be kept in its container, tightly closed, and out of the sight and reach of children.

Shelf-Life and Disposal

The device must be stored in its protective foil pouch until first use. It must be discarded when the dose counter reads “0” or 1 month after removal from the foil pouch, whichever occurs first. Disposal of the used or expired product must be carried out according to local regulations, and the user should consult a pharmacist for guidance on proper handling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Flutivent  found in:

A-Z Index: